title: Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction.
abstract: To evaluate the effects of lipoprotein (a) [Lp (a)] on the fibrinolytic system in patients with acute myocardial infarction (AMI) who underwent thrombolytic therapy with recombinant tissue-type plasminogen activator, we examined serial changes in plasma levels of Lp (a), plasminogen activator inhibitor (PAI) activity, alpha 2-plasmin inhibitor-plasmin complex (PIC) and thrombin antithrombin III complex (TAT) in venous plasma samples from 25 patients with AMI for 3 weeks. Plasma Lp (a) levels were significantly increased 5, 7, and 14 days after admission and tended to decrease by the 21st day. On the other hand, the ratio of PIC/TAT was significantly increased on the 7th day and remained high for 3 weeks (p < 0.01), while plasma PAI activity was significantly decreased on the 5th day after admission (p < 0.01). Thus, plasma fibrinolytic function is impaired in the early phase after AMI, and gradually improves over the course of 3 weeks. The increase in plasma Lp (a) levels is, therefore, not accompanied by a significant decrease in plasma fibrinolytic function in patients with AMI.
authors.affiliation: Division of Cardiology, Fukuoka Tokushukai Hospital, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Honda
authors.forename: S
authors.initials: S
authors.lastname: Oshima
authors.forename: H
authors.initials: H
authors.lastname: Ogawa
authors.forename: T
authors.initials: T
authors.lastname: Sakamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Miyao
authors.forename: S
authors.initials: S
authors.lastname: Sakata
authors.forename: O
authors.initials: O
authors.lastname: Hirashima
authors.forename: Y
authors.initials: Y
authors.lastname: Moriyama
authors.forename: H
authors.initials: H
authors.lastname: Yasue
mesh_terms: D000368:Aged; D000933:Antifibrinolytic Agents / Q000097:blood; D000990:Antithrombin III / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D009203:Myocardial Infarction / Q000097:blood*; D010447:Peptide Hydrolases / Q000032:analysis; D015849:Plasminogen Inactivators / Q000097:blood; D000979:alpha-2-Antiplasmin
chemical_list: D000933:Antifibrinolytic Agents; D017270:Lipoprotein(a); D015849:Plasminogen Inactivators; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D002097:C-Reactive Protein; D010447:Peptide Hydrolases; D005341:Fibrinolysin